Contact: [email protected]
| Title | Tumor type | Line | Study information |
|---|---|---|---|
| KEYNOTE-676 | Non-muscle invasive bladder carcinoma | Persistent or recurrent following BCG induction | Pembrolizumab + BCG |
Contact: [email protected]
| Title | Tumor type | Line | Study information |
|---|---|---|---|
| KEYNOTE-676 | Non-muscle invasive bladder carcinoma | Persistent or recurrent following BCG induction | Pembrolizumab + BCG |